ECSP066559A - - Google Patents
Info
- Publication number
- ECSP066559A ECSP066559A EC2006006559A ECSP066559A ECSP066559A EC SP066559 A ECSP066559 A EC SP066559A EC 2006006559 A EC2006006559 A EC 2006006559A EC SP066559 A ECSP066559 A EC SP066559A EC SP066559 A ECSP066559 A EC SP066559A
- Authority
- EC
- Ecuador
- Prior art keywords
- ghrelin
- diagnosis
- diseases
- nucleic acid
- specifically binds
- Prior art date
Links
- 102000012004 Ghrelin Human genes 0.000 abstract 3
- 101800001586 Ghrelin Proteins 0.000 abstract 3
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 abstract 2
- 230000000975 bioactive effect Effects 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- -1 n-octanoyl ghrelin Chemical compound 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- Plant Pathology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03025743 | 2003-11-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP066559A true ECSP066559A (enExample) | 2006-11-24 |
Family
ID=34610046
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2006006559A ECSP066559A (enExample) | 2003-11-10 | 2006-05-10 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20070031840A1 (enExample) |
| EP (1) | EP1682662A1 (enExample) |
| JP (1) | JP4823067B2 (enExample) |
| KR (1) | KR20060125743A (enExample) |
| CN (1) | CN1894407A (enExample) |
| AP (1) | AP2006003618A0 (enExample) |
| AU (1) | AU2004291656A1 (enExample) |
| BR (1) | BRPI0415872A (enExample) |
| CA (1) | CA2544805A1 (enExample) |
| CR (1) | CR8388A (enExample) |
| EA (1) | EA009376B1 (enExample) |
| EC (1) | ECSP066559A (enExample) |
| IL (1) | IL175443A0 (enExample) |
| MA (1) | MA28153A1 (enExample) |
| NO (1) | NO20062663L (enExample) |
| OA (1) | OA13282A (enExample) |
| TN (1) | TNSN06132A1 (enExample) |
| WO (1) | WO2005049828A1 (enExample) |
| ZA (1) | ZA200603435B (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003251681A1 (en) * | 2002-08-01 | 2004-02-23 | Noxxon Pharma Ag | Ghrelin binding nucleic acids |
| EP2290071B1 (en) | 2004-05-28 | 2014-12-31 | Asuragen, Inc. | Methods and compositions involving microRNA |
| EP2314688B1 (en) | 2004-11-12 | 2014-07-16 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
| UY29460A1 (es) * | 2005-04-08 | 2006-11-30 | Noxxon Pharma Ag | Acidos nucleicos de union a ghrelin |
| AU2007299828C1 (en) * | 2006-09-19 | 2014-07-17 | Interpace Diagnostics, Llc | MicroRNAs differentially expressed in pancreatic diseases and uses thereof |
| JP2010510964A (ja) * | 2006-09-19 | 2010-04-08 | アシュラジェン インコーポレイテッド | 治療的介入の標的としての、ｍｉＲ−１５、ｍｉＲ−２６、ｍｉＲ−３１、ｍｉＲ−１４５、ｍｉＲ−１４７、ｍｉＲ−１８８、ｍｉＲ−２１５、ｍｉＲ−２１６、ｍｉＲ−３３１、ｍｍｕ−ｍｉＲ−２９２−３ｐによって調節される遺伝子および経路 |
| CA2671299A1 (en) * | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | Functions and targets of let-7 micro rnas |
| CA2671294A1 (en) * | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | Mir-21 regulated genes and pathways as targets for therapeutic intervention |
| CN101622350A (zh) * | 2006-12-08 | 2010-01-06 | 奥斯瑞根公司 | 作为干预治疗靶标的miR-126调控基因和通路 |
| US20090175827A1 (en) * | 2006-12-29 | 2009-07-09 | Byrom Mike W | miR-16 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION |
| US20090131354A1 (en) * | 2007-05-22 | 2009-05-21 | Bader Andreas G | miR-126 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION |
| US20090232893A1 (en) * | 2007-05-22 | 2009-09-17 | Bader Andreas G | miR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION |
| WO2008154333A2 (en) * | 2007-06-08 | 2008-12-18 | Asuragen, Inc. | Mir-34 regulated genes and pathways as targets for therapeutic intervention |
| WO2009036332A1 (en) | 2007-09-14 | 2009-03-19 | Asuragen, Inc. | Micrornas differentially expressed in cervical cancer and uses thereof |
| WO2009052386A1 (en) * | 2007-10-18 | 2009-04-23 | Asuragen, Inc. | Micrornas differentially expressed in lung diseases and uses thereof |
| WO2009070805A2 (en) * | 2007-12-01 | 2009-06-04 | Asuragen, Inc. | Mir-124 regulated genes and pathways as targets for therapeutic intervention |
| WO2009086156A2 (en) * | 2007-12-21 | 2009-07-09 | Asuragen, Inc. | Mir-10 regulated genes and pathways as targets for therapeutic intervention |
| US20090263803A1 (en) * | 2008-02-08 | 2009-10-22 | Sylvie Beaudenon | Mirnas differentially expressed in lymph nodes from cancer patients |
| WO2009111643A2 (en) * | 2008-03-06 | 2009-09-11 | Asuragen, Inc. | Microrna markers for recurrence of colorectal cancer |
| WO2009154835A2 (en) * | 2008-03-26 | 2009-12-23 | Asuragen, Inc. | Compositions and methods related to mir-16 and therapy of prostate cancer |
| EP2285960B1 (en) | 2008-05-08 | 2015-07-08 | Asuragen, INC. | Compositions and methods related to mir-184 modulation of neovascularization or angiogenesis |
| WO2010056737A2 (en) * | 2008-11-11 | 2010-05-20 | Mirna Therapeutics, Inc. | Methods and compositions involving mirnas in cancer stem cells |
| WO2011053821A1 (en) | 2009-10-30 | 2011-05-05 | Tranzyme Pharma, Inc. | Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same |
| KR20140026357A (ko) * | 2011-01-10 | 2014-03-05 | 녹손 파르마 아게 | 목표 분자에 결합력을 갖는 핵산 및 이를 제조하는 방법 |
| WO2013040251A2 (en) | 2011-09-13 | 2013-03-21 | Asurgen, Inc. | Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5614395A (en) * | 1988-03-08 | 1997-03-25 | Ciba-Geigy Corporation | Chemically regulatable and anti-pathogenic DNA sequences and uses thereof |
| KR970002255B1 (ko) * | 1990-06-11 | 1997-02-26 | 넥스스타 파아마슈티컬드, 인크. | 핵산 리간드 |
| WO1996034879A1 (en) * | 1995-05-03 | 1996-11-07 | Whitehead Institute For Biomedical Research | Identification of enantiomeric ligands |
| US5780221A (en) * | 1995-05-03 | 1998-07-14 | Whitehead Institute For Biomedical Research | Identification of enantiomeric ligands |
| US20030211967A1 (en) * | 2001-05-07 | 2003-11-13 | Bryant Henry Uhlman | Method for selectively inhibiting ghrelin action |
| EP1286697A2 (en) * | 2000-05-17 | 2003-03-05 | Eli Lilly And Company | Method for selectively inhibiting ghrelin action |
| EP1353683A4 (en) * | 2000-05-30 | 2004-05-12 | Merck & Co Inc | ANALOGS BY GHRELIN |
| AU2003251681A1 (en) * | 2002-08-01 | 2004-02-23 | Noxxon Pharma Ag | Ghrelin binding nucleic acids |
| UY29460A1 (es) * | 2005-04-08 | 2006-11-30 | Noxxon Pharma Ag | Acidos nucleicos de union a ghrelin |
-
2004
- 2004-11-10 AP AP2006003618A patent/AP2006003618A0/xx unknown
- 2004-11-10 CN CNA2004800377977A patent/CN1894407A/zh active Pending
- 2004-11-10 US US10/578,938 patent/US20070031840A1/en not_active Abandoned
- 2004-11-10 KR KR1020067009024A patent/KR20060125743A/ko not_active Withdrawn
- 2004-11-10 JP JP2006538786A patent/JP4823067B2/ja not_active Expired - Fee Related
- 2004-11-10 EP EP04797787A patent/EP1682662A1/en not_active Ceased
- 2004-11-10 CA CA002544805A patent/CA2544805A1/en not_active Abandoned
- 2004-11-10 EA EA200600735A patent/EA009376B1/ru not_active IP Right Cessation
- 2004-11-10 OA OA1200600147A patent/OA13282A/en unknown
- 2004-11-10 WO PCT/EP2004/012739 patent/WO2005049828A1/en not_active Ceased
- 2004-11-10 AU AU2004291656A patent/AU2004291656A1/en not_active Abandoned
- 2004-11-10 BR BRPI0415872-5A patent/BRPI0415872A/pt not_active IP Right Cessation
-
2006
- 2006-05-02 ZA ZA200603435A patent/ZA200603435B/en unknown
- 2006-05-04 IL IL175443A patent/IL175443A0/en unknown
- 2006-05-09 TN TNP2006000132A patent/TNSN06132A1/fr unknown
- 2006-05-10 MA MA29015A patent/MA28153A1/fr unknown
- 2006-05-10 EC EC2006006559A patent/ECSP066559A/es unknown
- 2006-05-10 CR CR8388A patent/CR8388A/es not_active Application Discontinuation
- 2006-06-09 NO NO20062663A patent/NO20062663L/no not_active Application Discontinuation
-
2010
- 2010-02-24 US US12/711,415 patent/US20100261291A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP4823067B2 (ja) | 2011-11-24 |
| AU2004291656A1 (en) | 2005-06-02 |
| CN1894407A (zh) | 2007-01-10 |
| US20070031840A1 (en) | 2007-02-08 |
| US20100261291A1 (en) | 2010-10-14 |
| EA009376B1 (ru) | 2007-12-28 |
| CR8388A (es) | 2006-10-17 |
| BRPI0415872A (pt) | 2007-01-09 |
| NO20062663L (no) | 2006-08-09 |
| WO2005049828A1 (en) | 2005-06-02 |
| EP1682662A1 (en) | 2006-07-26 |
| AP2006003618A0 (en) | 2006-06-30 |
| KR20060125743A (ko) | 2006-12-06 |
| OA13282A (en) | 2007-01-31 |
| MA28153A1 (fr) | 2006-09-01 |
| TNSN06132A1 (fr) | 2007-11-15 |
| IL175443A0 (en) | 2006-09-05 |
| CA2544805A1 (en) | 2005-06-02 |
| EA200600735A1 (ru) | 2006-10-27 |
| ZA200603435B (en) | 2007-06-27 |
| JP2007513608A (ja) | 2007-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP066559A (enExample) | ||
| EA200800355A1 (ru) | Нейтрализующие антитела человека против b7rp1 | |
| MA29369B1 (fr) | Dosage fixe d'anticorps anti-her | |
| CR10530A (es) | Anticuerpos anti-dlla4 y metodos que los usan | |
| ECSP088508A (es) | Antagonistas de neuropilina | |
| NI201000055A (es) | 2' - fluoro - 2' - desoxitetrahidrouridinas como inhibidores de citidina desaminasa. | |
| BRPI0513029A (pt) | método para produzir uma proteìna de eritropoietina carbamilada, proteìna de eritropoietina carbamilada, composto, composição farmacêutica, métodos de tratamento de uma doença ou condição crÈnica, sub-crÈnica e aguda e de tratamento de uma doença do sistema nervoso central ou sistema nervoso periférico, e, uso de um composto | |
| EA200901166A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr 119 | |
| NO345046B1 (no) | Oral doseringsform | |
| MA30153B1 (fr) | Anticorps anti-ox40l et methodes correspondantes | |
| BRPI0509207A (pt) | moduladores canabinóides de tetraidro-indazol | |
| SV2010003494A (es) | Anticuerpos anti-cxcr5 humanizados, derivados de los mismos y su uso | |
| CU20120095A7 (es) | Antagonistas de pcsk9 | |
| ATE469895T1 (de) | Cgrp-rezeptorantagonisten | |
| SE0301653D0 (sv) | Novel compounds | |
| DK1778236T3 (da) | Modificerede pyrimidin-glucocorticoid-receptor-modulatorer | |
| MX2009003981A (es) | Agentes moduladores del receptor de calcio. | |
| DOP2005000025A (es) | Compuestos de heteroaril- y fenilsulfamoilo sustituidos | |
| BRPI0810130A8 (pt) | Composição de bebida, processo para produzir uma composição de bebida, e, uso de uma composição de bebida | |
| ECSP066883A (es) | Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes | |
| PA8675801A1 (es) | Anticuerpos anti-mcp-1, composiciones, metodos y usos | |
| BRPI0507308A (pt) | nanossuspensões de agentes anti-retrovirais para entrega ao sistema nervoso central aumentada | |
| PA8806501A1 (es) | Triazolotriazinas y triazolopirazinas y su uso | |
| HN2006029142A (es) | Proceso | |
| WO2006135694A3 (en) | Uii-modulating compounds and their use |